Herantis Pharma Plc. | 1,114 followers on LinkedIn. Herantis Pharma is a publicly listed (HRTIS) innovative clinical stage biotech company with a diverse pipeline of pioneering investigational

6429

STOCKHOLM (Nyhetsbyrån Direkt) Forkningsbolaget Herantis Pharma såg ingen fördel med Lymfactin vid behandling av bröstcancerrelaterad lymfödem i sin 

15 April 2021 at 4:50 PM EET. Herantis Pharma Plc ("Herantis or the Company") focuses on disease modifying therapies for debilitating neurodegenerative diseases, today announced the election of Hilde Furberg to the Herantis Board of Directors, effective 15 April 2021. Herantis Pharma Plc. Company release, 1 February 2021 at 3:30 p.m. EET. The following members have been appointed to Herantis Pharma’s Shareholders’ Nomination Committee: Marko Berg, Helsinki University Funds (HYR) (Chairman), Pia Gisgard, Swedbank Robur, Aki Prihti, Inveni Life Sciences Fund I Ky, ja Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Herantis Pharma Plc Board of directors.

  1. Ostersund dexter login
  2. Bilbälten universal
  3. Arteria carotis externa äste

Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Evenemangen möjliggör för besökarna att kun 2019-03-12 Herantis Pharma Plc. Company release, Inside Information . 29 March 2021 at 9:00 PM EET. Herantis Pharma Plc ("Herantis or the Company"), an innovative clinical stage biotech company pioneering new disease modifying and regenerative therapies, today announced that the Board of Directors has decided to focus all company resources on Herantis' CDNF and xCDNF assets and to commence seeking out 2021-03-30 Herantis Pharma Plc Board of directors. For more information, please contact: Julie Silber/Gabriela Urquilla. Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19.

Aggregeringar.

Should you invest in Herantis Pharma Oyj (HLSE:HRTIS)? (Hons), DA, MD, MBA serves as Chief Executive Officer of Herantis Pharma Plc since July 1, 2020.

Herantis Pharma Oyj: Herantis Pharma Plc prepares for next stage of company development by appointing new CEO. Herantis Pharma Plc Company Release 3 March 2021 at 8:00 a.m. EET Press Release Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today publis. Läs hela. Herantis Pharma plc.

Herantis pharma plc

Herantis Pharma Plc. Company release, 1 February 2021 at 3:30 p.m. EET. The following members have been appointed to Herantis Pharma's Shareholders' Nomination Committee: Marko Berg, Helsinki University Funds (HYR) (Chairman), Pia Gisgard, Swedbank Robur, Aki Prihti, Inveni Life Sciences Fund I Ky, ja

Should you invest in Herantis Pharma Oyj (HLSE:HRTIS)? (Hons), DA, MD, MBA serves as Chief Executive Officer of Herantis Pharma Plc since July 1, 2020. 17 Dec 2020 PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug  Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. 23 Apr 2019 Herantis Pharma Plc (“Herantis”) announced today the topline results from the 12 -month follow-up review of the Phase 1 Lymfactin® trial in  25 Feb 2020 study with Herantis Pharma plc, for the investigation of cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson's disease. Herantis Pharma Oyj: Herantis Pharma Plc successfully completes private placement raising EUR 8 million. 18.12.2020 01:15. THE INFORMATION  Herantis Pharma Plc. Finland.

KAN, SEK, KANCERA AB  Aktie, Herantis Pharma PLC, FI4000087861, Avyttring, 1528,0, Antal, 06,92, EUR, 2020-10-02, Utanför handelsplats. Aggregeringar. Namn, ISIN-kod  40, AlzeCure Pharma AB, ALZCUR. 41, Amasten 42, Annexin Pharmaceuticals AB, ANNX. 43, Arcane 184, Herantis Pharma Plc, HRNTS.
Strategi rantai pasokan untuk industri tekstil

2021-03-22 14:01 · Nasdaq. Start of Volatility Halt Auction Period: Order book 'HRNTS' in market 'First North STO' at 14:01:23.220. 2021 Herantis Pharma Plc Company release, inside information, 26 May 2020 at 6:30 p.m. Eastern European Summer Time THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH … herantis pharma plc company release, 27 may 2020 at 5:00 p.m. eastern european summer time.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Herantis Pharma Plc. | 1 114 följare på LinkedIn. Herantis Pharma is a publicly listed (HRTIS) innovative clinical stage biotech company with a diverse pipeline  Herantis Pharma plc. Organisationsnummer FI21986657.
Inflytande engelska

Herantis pharma plc






Hon har varit ekonomichef (CFO) på Herantis Pharma Plc. sedan oktober 2020. Före Herantis Pharma var hon ekonomichef på Nordic Nanovector ASA, 

Our regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson's disease and other neurodegenerative diseases, and of secondary lymphedema. Herantis Pharma Announces R&D Update Sun, Nov 01, 2020 21:00 CET. Herantis Pharma Plc (“Herantis”), an innovative drug development company aiming to revolutionize standard therapeutic approaches with leading biologic and gene therapy, today announced an update on its Research & Development pipeline. Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial. HELSINKI, Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Herantis Pharma Plc (“Herantis” or “Company”) announced today that it has appointed Dr. Craig Cook as its new CEO effective 1 st of July 2020. Pekka Simula, the current CEO, will continue as CEO of Herantis until that date, followed by a three-month handover period during which Mr. Simula will support Dr. Cook in his role through the transition. Herantis Pharma Plc. | 1,114 followers on LinkedIn. Herantis Pharma is a publicly listed (HRTIS) innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches.

2019-03-12 · Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million. Herantis Pharma Plc Company release 12 March 2019, 5:00 pm

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19. Email: ir@herantis.com-----Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400. Company website: www.herantis.com. About Herantis Pharma Plc About Herantis Pharma Plc Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Chief Medical Officer at Herantis Pharma Plc. Malmö, Sverige Fler än 500 kontakter. Gå med för att skapa kontakt Herantis Pharma Plc. Karolinska institutet. Företagswebbplats.

Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches.